Mereo BioPharma Group plc – Sponsored ADR $MREO Stock Holdings Raised by Aberdeen Group plc

Aberdeen Group plc lifted its stake in shares of Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) by 82.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,538,699 shares of the company’s stock after purchasing an additional 2,509,827 shares during the period. Aberdeen Group plc owned about 3.48% of Mereo BioPharma Group worth $11,410,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in Mereo BioPharma Group by 0.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock worth $4,783,000 after buying an additional 6,068 shares during the last quarter. Marex Group plc bought a new position in Mereo BioPharma Group during the second quarter worth $27,000. Significant Wealth Partners LLC boosted its holdings in Mereo BioPharma Group by 114.8% in the third quarter. Significant Wealth Partners LLC now owns 47,814 shares of the company’s stock worth $98,000 after purchasing an additional 25,553 shares during the period. Forefront Wealth Partners LLC bought a new stake in Mereo BioPharma Group during the third quarter valued at $68,000. Finally, Clear Harbor Asset Management LLC raised its holdings in shares of Mereo BioPharma Group by 83.3% during the third quarter. Clear Harbor Asset Management LLC now owns 77,000 shares of the company’s stock worth $159,000 after purchasing an additional 35,000 shares during the period. 62.83% of the stock is owned by institutional investors.

Key Headlines Impacting Mereo BioPharma Group

Here are the key news stories impacting Mereo BioPharma Group this week:

• Negative Sentiment: Multiple national plaintiff firms have announced a class action or solicited investors over purchases of Mereo ADS between June 5, 2023 and Dec. 26, 2025 and are urging potential lead plaintiffs to come forward before the April 6, 2026 deadline — heightening litigation risk and uncertainty for shareholders. Pomerantz Investor Alert
• Negative Sentiment: Several other firms (Rosen, Faruqi & Faruqi, Berger Montague, Wolf Haldenstein, Portnoy, Gross, Robbins and others) have issued similar notices — reinforcing media coverage and increasing the likelihood of consolidated litigation and discovery costs. Example notice: Rosen Law Notice
• Negative Sentiment: Plaintiff firm Levi & Korsinsky published a quantified investor-damages estimate of $2.02 per share tied to the Phase 3 disclosure — a concrete dollar figure that can shape settlement expectations and investor losses calculations. Levi & Korsinsky Damages Note
• Negative Sentiment: Robbins LLP and others are publicly investigating allegations that Mereo misled investors about the Phase 3 ORBIT and COSMIC studies for setrusumab — these allegations are the core driver of the litigation risk and could lead to prolonged legal proceedings and reputational damage. Robbins LLP Investigation

Mereo BioPharma Group Trading Up 2.6%

Shares of NASDAQ MREO opened at $0.43 on Friday. Mereo BioPharma Group plc – Sponsored ADR has a twelve month low of $0.20 and a twelve month high of $3.05. The company has a market capitalization of $68.74 million, a price-to-earnings ratio of -7.20 and a beta of 0.37. The firm has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.50.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MREO. Needham & Company LLC dropped their price target on Mereo BioPharma Group from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating and issued a $1.00 target price on shares of Mereo BioPharma Group in a research report on Friday, January 16th. Lifesci Capital cut Mereo BioPharma Group from an “outperform” rating to a “hold” rating in a research note on Monday, December 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Finally, Wall Street Zen cut shares of Mereo BioPharma Group from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.